Bacteria Can Help Improve Vaccine Response: Study
"); jQuery("#212 h3").html("

"); });
2021-12-02 HKT 13:46
Researchers from two local universities say a study they have carried out suggests that supplementing a type of bacteria in the gut can help improve a person's antibody response to Covid vaccinations.
The research team from the medical faculties of Chinese University and the University of Hong Kong collected blood and stool samples from 138 vaccinated people aged between 18 and 67, between April and August.
They found that 57 percent of the participants who received the Sinovac vaccine did not have enough antibodies against Covid.
They said they also found a close correlation between the presence of the Bifidobacterium adolescentis and a person's antibody response to Covid vaccinations, saying participants lacking the bacteria tended to have a low antibody response.
Professor Ng Siew-Chien, associate director of Chinese University's Centre for Gut Microbiota Research, said people cannot absorb the bacteria through their diet, but they could in future be given probiotics to boost the presence of the bacteria.
“I think this supplementation of Bifidobacterium adolescentis is going to really complement the global vaccination, regardless of whether it’s BioNTech or whether it’s Sinovac, because it can actually help to hopefully increase antibody level response in certain more susceptible population. So that in future, there may be a chance that this will be incorporated into the vaccination programme, because it’s healthy, it’s safe, and it doesn’t cause any side effect or harm,” she said.
“A lot of what is available in terms of probiotics may not have this bacteria, because you need special technology to capsulise the bacteria so that it can survive, so that when you consume it, it will actually reach your gut. So we encourage that when people are thinking about probiotics, do look very carefully whether the actual product has this type of bacteria and there are studies to support its use.”
In a previous study conducted by Chinese University, researchers found that around 50 percent of 2,000 participants in Hong Kong did not have Bifidobacterium adolescentis at all, while around 34 percent only had a low level of the bacteria.
Researchers said there are many factors that could reduce the number of the bacteria in a person's gut, including old age and an unhealthy diet.
They said they are also carrying out a clinical study on some 500 people deemed to be more high-risk from Covid, including the elderly and people with diabetes and obesity, to find out more about the effectiveness of probiotics on improving their antibody response. They said they hope to release their findings early next year.
ZA Bank Brings Nasdaq Data To Hong Kong, Expanding US Stock Access And Investor Education
ZA Bank and Nasdaq have announced a collaboration aimed at enhancing digital wealth management in Hong Kong and interna... Read more
Hong Kong To Study One‑Stop Infrastructure For Equities, Bonds And Digital Assets
The Hong Kong Monetary Authority’s (HKMA) CMU OmniClear and the Hong Kong Exchange (HKEX) are set to begin a study on... Read more
Hong Kong To Issue First Stablecoin Licenses In March, Expand Crypto Regulation
Hong Kong will issue its first licenses for fiat-referenced stablecoin issuers in March and introduce new legislation l... Read more
MSIG Joins US$6B IFC Credit Insurance Facility To Boost Emerging Market Lending
MSIG USA and Mitsui Sumitomo Insurance (MSI Japan), together referred to as MSIG, have joined a new insurance-ba... Read more
Why The $2 Trillion Stablecoin Prediction Is Too Low
McKinsey estimates the stablecoin market will hit $2 trillion by 2028. But according to Sam Lin, COO of dtcpay, even th... Read more
RedotPay Eyes US IPO With Potential US$1 Billion Raise
RedotPay is reportedly exploring an IPO in the US that could raise more than US$1 billion, according to people famili... Read more